From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 3m
LifeMD's AT&T bet: free users to paying patients
LifeMD partners with AT&T to reach 100 million customers, but the path from free membership to paid services remains unproven.
In brief
LifeMD partners with AT&T to reach 100 million customers, but the path from free membership to paid services remains unproven. LifeMD's profitability depends entirely on converting AT&T's free members into paying customers at rates that justify the acquisition costs, which won't be clear until late 2026 earnings…
LifeMD grows subscribers but revenue falls
LifeMD reported Q2 2026 revenue of $47.28 million, down 4% year-over-year, despite adding 20% more subscribers to reach 356,000 total. The company is shifting toward higher-margin GLP-1 therapies and longer memberships.
Margins improve despite subscriber shift
Gross margin expanded to 89% in Q2 2026 from 86% in the prior year, showing the core telehealth model remains profitable even as the company transitions its product mix and customer acquisition strategy.
AT&T partnership launches September 2026
LifeMD announced a partnership with AT&T on September 15, 2026, offering free memberships to eligible AT&T customers while charging separately for visits ($29-$79) and prescriptions. Initial rollout covers 11 states reaching 29 million customers.
Partnership waives $228 annual membership fee
AT&T customers get free access to LifeMD's platform, eliminating the $19 monthly membership fee. Revenue must come from visit fees and prescriptions, creating a two-stage monetization challenge: enrollment doesn't guarantee paid utilization.
Per-lead fee structure remains secret
LifeMD will pay AT&T a fixed fee per lead, but the SEC filing doesn't disclose the amount or any minimum commitments. This creates material uncertainty around true acquisition costs and partnership profitability.
Nationwide expansion planned for January 2027
The 11-state pilot reaching 29 million customers will expand nationwide in January 2027 to reach over 100 million eligible customers. This phased approach allows LifeMD to test conversion metrics before full-scale deployment.
One-year contract with 90-day exit clause
The partnership has a one-year initial term with automatic annual renewals, but either party can exit with 90 days' notice. This limits long-term downside if utilization disappoints but prevents LifeMD from recouping acquisition investments across multiple years.
Management guides to Q4 profitability inflection
LifeMD projects Q4 2026 revenue of $60-$64 million with EBITDA of $3-$6 million, implying an annualized run rate of $250 million revenue and $22 million EBITDA. This assumes successful partnership ramp and customer retention.
Partnership spending could accelerate cash burn
If LifeMD pays AT&T $5-$10 per lead and achieves a 5% enrollment rate across 29 million initial customers, the company could spend $7-$14 million on acquisition in the pilot phase alone, increasing reliance on equity sales.
Conversion rates are the critical unknown
The partnership's success depends on converting free AT&T members to paid services at rates sufficient to justify acquisition costs. Q3 and Q4 2026 earnings will provide the first visibility into actual conversion metrics.
Valuation hinges on three key metrics
Investors should track AT&T enrollment rates, paid utilization conversion rates, and customer acquisition cost per paying patient versus LifeMD's historical standalone CAC. If these metrics meet expectations, the partnership could drive significant multiple expansion.
2027 earnings estimates show wide uncertainty
Analyst consensus for 2027 ranges from negative $0.07 to positive $0.17 per share, reflecting significant uncertainty about the profitability inflection. The wide range suggests market participants are pricing in substantial execution risk.
Equity dilution risk if spending exceeds plans
Management stated existing cash and at-the-market equity sales will fund operations for at least 12 months. If partnership acquisition spending exceeds expectations, the company will need additional equity financing, diluting existing shareholders.
The headline
LifeMD's profitability depends entirely on converting AT&T's free members into paying customers at rates that justify the acquisition costs, which won't be clear until late 2026 earnings.
